Skip to main
IDYA

IDYA Stock Forecast & Price Target

IDYA Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 64%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

IDEAYA Biosciences Inc. demonstrates a robust outlook due to the increasing probability of success (PoS) for its lead program, darovasertib, which is showing promising anti-tumor responses in early clinical studies. The synergistic effect observed when combined with crizotinib suggests enhanced efficacy and safety, bolstering expectations for robust performance in ongoing Phase 3 trials which may yield favorable results. Furthermore, IDEAYA's strategic focus on high-value oncology targets, alongside an anticipated peak revenue potential exceeding $3 billion, reinforces the positive growth trajectory for the company's stock.

Bears say

IDEAYA Biosciences Inc. faces a negative outlook primarily due to the unpredictability surrounding its future revenues and expenses, compounded by its current non-revenue-generating status. Key risks include potential negative trial outcomes for its product candidates, particularly IDE397 and IDE849, which could limit market potential and weaken investor confidence in the pipeline. Additionally, the company’s reliance on a single product, darovasertib (daro), exposes it to significant concentration risks, as any setbacks in clinical or commercial execution could adversely affect overall performance.

IDYA has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 64% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ideaya Biosciences Inc (IDYA) Forecast

Analysts have given IDYA a Buy based on their latest research and market trends.

According to 11 analysts, IDYA has a Buy consensus rating as of Jan 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ideaya Biosciences Inc (IDYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.